Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurotherapeutics
Published in: Neurotherapeutics 4/2015

01-10-2015 | Review

Cannabinoids and Schizophrenia: Risks and Therapeutic Potential

Authors: Marc W. Manseau, Donald C. Goff

Published in: Neurotherapeutics | Issue 4/2015

Login to get access

Abstract

A convergence of evidence shows that use of Cannabis sativa is associated with increased risk of developing psychotic disorders, including schizophrenia, and earlier age at which psychotic symptoms first manifest. Cannabis exposure during adolescence is most strongly associated with the onset of psychosis amongst those who are particularly vulnerable, such as those who have been exposed to child abuse and those with family histories of schizophrenia. Schizophrenia that develops after cannabis use may have a unique clinical phenotype, and several genetic polymorphisms may modulate the relationship between cannabis use and psychosis. The endocannabinoid system has been implicated in psychosis both related and unrelated to cannabis exposure, and studying this system holds potential to increase understanding of the pathophysiology of schizophrenia. Anandamide signaling in the central nervous system may be particularly important. Δ9-Tetrahydrocannabinol in cannabis can cause symptoms of schizophrenia when acutely administered, and cannabidiol (CBD), another compound in cannabis, can counter many of these effects. CBD may have therapeutic potential for the treatment of psychosis following cannabis use, as well as schizophrenia, possibly with better tolerability than current antipsychotic treatments. CBD may also have anti-inflammatory and neuroprotective properties. Establishing the role of CBD and other CBD-based compounds in treating psychotic disorders will require further human research.
Appendix
Available only for authorised users
Literature
1.
Kendler KS, Gallagher TJ, Abelson JM, Kessler RC. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey. Arch Gen Psychiatry 1996;52:1022-1031.CrossRef
2.
Tandon R, Gaebel W, Barch DM, et al. Definition and description of schizophrenia in the DSM-5. Schizophr Res 2013;150:3-10.CrossRefPubMed
3.
Iseger TA, Bossong MG. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res 2015;162:153-161.CrossRefPubMed
4.
5.
Clausen L, Hjorthoj CR, Thorup A, et al. Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: a 5-year follow-up study of patients in the OPUS trial. Psychol Med 2014;44:117-126.CrossRefPubMed
6.
Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannibis and schizophrenia: A longitudinal study of Swedish conscripts. Lancet 1987;2:1483-1485.CrossRefPubMed
7.
Moore THM, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007;370:319-328.CrossRefPubMed
8.
Minozzi S, Davoli M, Bargagli AM, Amato L, Vecchi S, Perucci CA. An overview of systematic reviews on cannabis and psychosis: discussing apparently conflicting results. Drug Alcohol Rev 2010;29:304-317.CrossRefPubMed
9.
Rowe AR, Mercer L, Casetti V, et al. Dementia praecox redux: A systematic review of the nicotinic receptor as a target for cognitive symptoms of schizophrenia. J Psychopharmacol 2015;29:197-211.CrossRefPubMed
10.
Power RA, Verweij KJ, Zuhair M, et al. Genetic predisposition to schizophrenia associated with increased use of cannabis. Mol Psychiatry 2014;19:1201-1204.PubMedCentralCrossRefPubMed
11.
Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry 2011;68:555-561.CrossRefPubMed
12.
Schimmelmann BG, Conus P, Cotton SM, et al. Cannabis use disorder and age at onset of psychosis--a study in first-episode patients. Schizophr Res 2011;129:52-56.CrossRefPubMed
13.
Stefanis NC, Dragovic M, Power BD, Jablensky A, Castle D, Morgan VA. Age at initiation of cannabis use predicts age at onset of psychosis: the 7- to 8-year trend. Schizophr Bull 2013;39:251-254.PubMedCentralCrossRefPubMed
14.
van Gastel WA, Wigman JT, Monshouwer K, et al. Cannabis use and subclinical positive psychotic experiences in early adolescence: findings from a Dutch survey. Addiction 2012;107:381-387.CrossRefPubMed
15.
Ferdinand RF, Sondeijker F, van der Ende J, Selten JP, Huizink A, Verhulst FC. Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 2005;100:612-618.CrossRefPubMed
16.
Henquet C, Krabbendam L, Spauwen J, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005;330:1-5.CrossRef
17.
McGrath J, Welham J, Scott J, et al. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry 2010;67:440-447.CrossRefPubMed
18.
Macleod J, Oakes R, Copello A, et al. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet 2004;363:1579-1588.CrossRefPubMed
19.
Gage SH, Zammit S, Hickman M. Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population. F1000 Med Rep. 2013;5:2.PubMedCentralCrossRefPubMed
20.
Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychol Med 2003;33:15-21.PubMed
21.
Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreasson S, Allebeck P. Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. Psychol Med 2012;42:1321-1328.CrossRefPubMed
22.
23.
Degenhardt L, Hall W. Is cannabis a contributory cause of psychosis? Can J Psychiatry2006;51:556-565.PubMed
24.
Bersani G, Orlandi V, Kotzalidis GD, Pancheri P. Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. Eur Arch Psychiatry Clin Neurosci 2002;252:86-92.CrossRefPubMed
25.
Arendt M, Mortensen PB, Rosenberg R, Pedersen CB, Waltoft BL. Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia. Arch Gen Psychiatry 2008;65:1269-1274.CrossRefPubMed
26.
Alemany S, Arias B, Fatjo-Vilas M, et al. Psychosis-inducing effects of cannabis are related to both childhood abuse and COMT genotypes. Acta Psychiatr Scand 2014;129:54-62.CrossRefPubMed
27.
Vinkers CH, Van Gastel WA, Schubart CD, et al. The effect of childhood maltreatment and cannabis use on adult psychotic symptoms is modified by the COMT Val(1)(5)(8)Met polymorphism. Schizophr Res 2013;150:303-311.CrossRefPubMed
28.
Konings M, Stefanis N, Kuepper R, et al. Replication in two independent population-based samples that childhood maltreatment and cannabis use synergistically impact on psychosis risk. Psychol Med 2012;42:149-159.CrossRefPubMed
29.
Houston JE, Murphy J, Shevlin M, Adamson G. Cannabis use and psychosis: re-visiting the role of childhood trauma. Psychol Med 2011;41:2339-2348.CrossRefPubMed
30.
Harley M, Kelleher I, Clarke M, et al. Cannabis use and childhood trauma interact additively to increase the risk of psychotic symptoms in adolescence. Psychol Med 2010;40:1627-1634.CrossRefPubMed
31.
Compton MT, Furman AC, Kaslow NJ. Preliminary evidence of an association between childhood abuse and cannabis dependence among African American first-episode schizophrenia-spectrum disorder patients. Drug Alcohol Depend 2004;76:311-316.CrossRefPubMed
32.
Kuepper R, van Os J, Lieb R, Wittchen HU, Henquet C. Do cannabis and urbanicity co-participate in causing psychosis? Evidence from a 10-year follow-up cohort study. Psychol Med 2011;41:2121-2129.CrossRefPubMed
33.
Yucel M, Bora E, Lubman DI, et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull 2012;38:316-330.PubMedCentralCrossRefPubMed
34.
Compton MT, Broussard B, Ramsay CE, Stewart T. Pre-illness cannabis use and the early course of nonaffective psychotic disorders: associations with premorbid functioning, the prodrome, and mode of onset of psychosis. Schizophr Res 2011;126:71-76.PubMedCentralCrossRefPubMed
35.
Burns JK. Cannabis use and duration of untreated psychosis: a systematic review and meta-analysis. Curr Pharm Des 2012;18:5093-5104.CrossRefPubMed
36.
Loberg EM, Helle S, Nygard M, Berle JO, Kroken RA, Johnsen E. The cannabis pathway to non-affective psychosis may reflect less neurobiological vulnerability. Front Psychiatry 2014;5:159.PubMedCentralPubMed
37.
Ruiz-Veguilla M, Callado LF, Ferrin M. Neurological soft signs in patients with psychosis and cannabis abuse: a systematic review and meta-analysis of paradox. Curr Pharm Des 2012;18:5156-5164.CrossRefPubMed
38.
Barrowclough C, Gregg L, Lobban F, Bucci S, Emsley R. The impact of cannabis use on clinical outcomes in recent onset psychosis. Schizophr Bull 2015;41:382-390.CrossRefPubMed
39.
Stone JM, Fisher HL, Major B, et al. Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation. Psychol Med 2014;44:499-506.CrossRefPubMed
40.
Decoster J, van Os J, Myin-Germeys I, De Hert M, van Winkel R. Genetic variation underlying psychosis-inducing effects of cannabis: critical review and future directions. Curr Pharm Des 2012;18:5015-5023.CrossRefPubMed
41.
Decoster J, van Os J, Kenis G, et al. Age at onset of psychotic disorder: cannabis, BDNF Val66Met, and sex-specific models of gene-environment interaction. Am J Med Genet B Neuropsychiatr Genet 2011;156B:363-369.CrossRefPubMed
42.
Colizzi M, Fazio L, Ferranti L, et al. Functional genetic variation of the cannabinoid receptor 1 and cannabis use interact on prefrontal connectivity and related working memory behavior. Neuropsychopharmacology 2015;40:640-649.CrossRefPubMed
43.
Chavarria-Siles I, Contreras-Rojas J, Hare E, et al. Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2008;147:279-284.CrossRefPubMed
44.
Ujike H, Takaki M, Nakata K, et al. CNRI, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 2002;7:515-518.CrossRefPubMed
45.
Ermis A, Erkiran M, Dasdemir S, et al. The relationship between catechol-O-methyltransferase gene Val158Met (COMT) polymorphism and premorbid cannabis use in Turkish male patients with schizophrenia. In Vivo 2015;29:129-132.PubMed
46.
Zammit S, Owen MJ, Evans J, Heron J, Lewis G. Cannabis, COMT and psychotic experiences. Br J Psychiatry 2011;199:380-385.CrossRefPubMed
47.
Di Forti M, Iyegbe C, Sallis H, et al. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry 2012;72:811-816.CrossRefPubMed
48.
van Winkel R, van Beveren NJ, Simons C, Genetic R, Outcome of Psychosis I. AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmacology 2011;36:2529-2537.PubMedCentralCrossRefPubMed
49.
Muller-Vahl KR, Emrich HM. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert Rev Neurother 2008;8:1037-1048.CrossRefPubMed
50.
Kucerova J, Tabiova K, Drago F, Micale V. Therapeutic potential of cannabinoids in schizophrenia. Recent Pat CNS Drug Discov 2014;9:13-25.CrossRefPubMed
51.
Bioque M, Garcia-Bueno B, Macdowell KS, et al. Peripheral endocannabinoid system dysregulation in first-episode psychosis. Neuropsychopharmacology 2013;38:2568-2577.PubMedCentralCrossRefPubMed
52.
Wenzel JM, Cheer JF. Endocannabinoid-dependent modulation of phasic dopamine signaling encodes external and internal reward-predictive cues. Front Psychiatry 2014;5:118.PubMedCentralCrossRefPubMed
53.
54.
van Winkel R, Kuepper R. Epidemiological, neurobiological, and genetic clues to the mechanisms linking cannabis use to risk for nonaffective psychosis. Annu Rev Clin Psychol 2014;10:767-791.CrossRefPubMed
55.
Monory K, Polack M, Remus A, Lutz B, Korte M. Cannabinoid CB1 receptor calibrates excitatory synaptic balance in the mouse hippocampus. J Neurosci 2015;35:3842-3850.CrossRefPubMed
56.
Tahmasebi L, Komaki A, Karamian R, et al. The interactive role of cannabinoid and vanilloid systems in hippocampal synaptic plasticity in rats. Eur J Pharmacol 2015;757:68-73.CrossRefPubMed
57.
Leweke FM. Anandamide dysfunction in prodromal and established psychosis. Curr Pharm Des 2012;18:5188-5193.CrossRefPubMed
58.
Koethe D, Giuffrida A, Schreiber D, et al. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry 2009;194:371-372.CrossRefPubMed
59.
Giuffrida A, Leweke FM, Gerth CW, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004;29:2108-2114.CrossRefPubMed
60.
Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999;10:1665-1669.CrossRefPubMed
61.
Leweke FM, Giuffrida A, Koethe D, et al. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res 2007;94:29-36.CrossRefPubMed
62.
Morgan CJ, Page E, Schaefer C, et al. Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms. Br J Psychiatry 2013;202:381-382.CrossRefPubMed
63.
Pistis M, Ferraro L, Pira L, et al. Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res 2002;948:155-158.CrossRefPubMed
64.
D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004;29:1558-1572.CrossRefPubMed
65.
Morrison PD, Zois V, McKeown DA, et al. The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 2009;39:1607-1616.CrossRefPubMed
66.
D'Souza DC, Abi-Saab WM, Madonick S, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005;57:594-608.CrossRefPubMed
67.
Liem-Moolenaar M, te Beek ET, de Kam ML, et al. Central nervous system effects of haloperidol on THC in healthy male volunteers. J Psychopharmacol 2010;24:1697-1708.CrossRefPubMed
68.
D'Souza DC, Braley G, Blaise R, et al. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology 2008;198:587-603.PubMedCentralCrossRefPubMed
69.
Di Forti M, Marconi A, Carra E, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2015;2:233-238.CrossRefPubMed
70.
Di Forti M, Sallis H, Allegri F, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull 2014;40:1509-1517.CrossRefPubMed
71.
van Amsterdam J, Brunt T, van den Brink W. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol 2015;29:254-263.CrossRefPubMed
72.
Levin R, Almeida V, Peres FF, et al. Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. Curr Pharm Des 2012;18:4960-4965.CrossRefPubMed
73.
Roser P, Haussleiter IS. Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies. Curr Pharm Des 2012;18:5141-5155.CrossRefPubMed
74.
Kelly DL, Gorelick DA, Conley RR, et al. Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol 2011;31:86-91.PubMedCentralCrossRefPubMed
75.
Boggs DL, Kelly DL, McMahon RP, et al. Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial. Schizophr Res 2012;134:207-210.PubMedCentralCrossRefPubMed
76.
Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012;2:e94.PubMedCentralCrossRefPubMed
77.
Yang K, Lei G, Xie YF, MacDonald JF, Jackson MF. Differential regulation of NMDAR and NMDAR-mediated metaplasticity by anandamide and 2-AG in the hippocampus. Hippocampus 2014;24:1601-1614.CrossRefPubMed
78.
Chavez AE, Chiu CQ, Castillo PE. TRPV1 activation by endogenous anandamide triggers postsynaptic long-term depression in dentate gyrus. Nat Neurosci 2010;13:1511-1518.PubMedCentralCrossRefPubMed
79.
Martin-Santos R, Crippa JA, Batalla A, et al. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr Pharm Des 2012;18:4966-4979.CrossRefPubMed
80.
Englund A, Morrison PD, Nottage J, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 2013;27:19-27.CrossRefPubMed
81.
Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010;35:764-774.PubMedCentralCrossRefPubMed
82.
Klein C, Karanges E, Spiro A, et al. Cannabidiol potentiates Delta(9)-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology 2011;218:443-457.CrossRefPubMed
83.
Morgan CJ, Gardener C, Schafer G, et al. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med 2012;42:391-400.CrossRefPubMed
84.
Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 2008;192:306-307.CrossRefPubMed
85.
Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MP. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 2011;130:216-221.CrossRefPubMed
86.
Hermann D, Sartorius A, Welzel H, et al. Dorsolateral prefrontal cortex N-acetylaspartate/total creatine (NAA/tCr) loss in male recreational cannabis users. Biol Psychiatry 2007;61:1281-1289.CrossRefPubMed
87.
Hermann D, Schneider M. Potential protective effects of cannabidiol on neuroanatomical alterations in cannabis users and psychosis: a critical review. Curr Pharm Des 2012;18:4897-4905.CrossRefPubMed
88.
Demirakca T, Sartorius A, Ende G, et al. Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug Alcohol Depend 2011;114:242-245.PubMed
89.
Schubart CD, Sommer IE, Fusar-Poli P, de Witte L, Kahn RS, Boks MP. Cannabidiol as a potential treatment for psychosis. Eur Neuropsychopharmacol 2014;24:51-64.CrossRefPubMed
90.
Gomes FV, Llorente R, Del Bel EA, Viveros MP, Lopez-Gallardo M, Guimaraes FS. Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol. Schizophr Res 2015;164:155-163.CrossRefPubMed
91.
Zuardi AW, Morais SL, Guimarães FS, Mechoulam R. Antipsychotic effect of cannabidiol. J Clin Psychiatry 1995;56:485-486.PubMed
92.
Zuardi AW, Hallak JE, Dursun SM, et al. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol 2006;20:683-686.CrossRefPubMed
93.
Zuardi AW, Crippa JAS, Hallak JEC, et al. Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol 2009;23:979-983.CrossRefPubMed
94.
Hallak JEC, Machado-de-Sousa JP, Crippa JAS, et al. Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). Rev Bras Psiquiatr 2010;31:56-61.
Metadata
Title
Cannabinoids and Schizophrenia: Risks and Therapeutic Potential
Authors
Marc W. Manseau
Donald C. Goff
Publication date
01-10-2015
Publisher
Springer US
Published in
Neurotherapeutics / Issue 4/2015
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-015-0382-6

Other articles of this Issue 4/2015

Neurotherapeutics 4/2015 Go to the issue

Review

Cannabinoids and Epilepsy

Review

Endocannabinoid Signaling in Autism

Editorial

Cannabinoids in the Treatment of Neurological Disorders

Review

Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics

Review

Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage

Review

The Endocannabinoid System and its Modulation by Phytocannabinoids